{"name":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","slug":"fondazione-i-r-c-c-s-istituto-neurologico-carlo-besta","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Bridge therapy","genericName":"Bridge therapy","slug":"bridge-therapy","indication":"Transitional therapy during treatment switches in neurological conditions","status":"marketed"},{"name":"Symptomatic drugs","genericName":"Symptomatic drugs","slug":"symptomatic-drugs","indication":"Symptomatic management of neurological disorders","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Prophylactic","genericName":"Prophylactic","slug":"prophylactic","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Bridge therapy","genericName":"Bridge therapy","slug":"bridge-therapy","phase":"marketed","mechanism":"Bridge therapy refers to a transitional treatment strategy that maintains disease control while switching between long-term therapies.","indications":["Transitional therapy during treatment switches in neurological conditions"],"catalyst":""},{"name":"Prophylactic","genericName":"Prophylactic","slug":"prophylactic","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Symptomatic drugs","genericName":"Symptomatic drugs","slug":"symptomatic-drugs","phase":"marketed","mechanism":"Symptomatic drugs provide relief from disease symptoms without targeting the underlying pathological mechanism.","indications":["Symptomatic management of neurological disorders"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBhNkg0c1RFU1RiUU5WVGZPTThHTnl3OUNMYUV5RG9uTFJMOVRubTNpam9fUE02UDdRU3lWcE1MVmduUW1ETHBjaTAydEtJcmprNHRpdTNnMFg4NGZidEt3?oc=5","date":"2025-11-13","type":"pipeline","source":"nature.com","summary":"Metabolic reprogramming in amyotrophic lateral sclerosis ependymal stem cells by FM19G11 nanotherapy - nature.com","headline":"Metabolic reprogramming in amyotrophic lateral sclerosis ependymal stem cells by FM19G11 nanotherapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxOT3NQdEd6bTJONzZNanVoV0xXcmZzOWdnUHZIRGVPOUs4RkpUb1ZyekdFdHJwY0FLREd1a3dueUFEWkN3cFdxVHE1TTk2cExEdXRnNExXTV9PdGJjRTg3NEExWmdpbnFLcXpoQV9MMHg1YUQ0UWFWRkYwbVZOaDVrLXRkaXAtV19DbThoQ3FoWEczTE9WMzBEck9EU25jNWt5WlhlSjBxRHpVNF9odjRlUDB1Q1pnYm0xNTVuVTI4N0xWd0lhQWFSV1hTaWpzSlh1RFhVNkVfRGRFM1EwUm0zcFlXNjVNWFQxQXpwSkFLbXJicnktd2RlcQ?oc=5","date":"2025-03-03","type":"pipeline","source":"Ricerca Malattie Genetiche Rare","summary":"A platform dedicated to Duchenne Muscular Dystrophy - Ricerca Malattie Genetiche Rare","headline":"A platform dedicated to Duchenne Muscular Dystrophy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE5EOEJ3dUJkVHhRRVRpV2NnRmZXeE1zYkV2WG5rNDVRRkFIUHpUNWdMc3BlREExT3BYdlA2UXpDakFBZDhfRWZ3SjFnS0dFYWZSN1hKWlpaSFNqWTRVQTdLZ1Znc1M?oc=5","date":"2024-03-19","type":"pipeline","source":"MedPage Today","summary":"Major Congenital Malformation Risk Lower With Several Epilepsy Drugs - MedPage Today","headline":"Major Congenital Malformation Risk Lower With Several Epilepsy Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE9PT1ZuMDJUYk9pTDBZTkhBWVFieVl3SUhDWHBGZm9CQmFNX2lZZ3JCcXB4S1NWaEY5aTlaa1BNYmtkYnhYbFJMLUJ5eWhmejhOVDlGcWh6Nk1fdGg0Z2xsZ3ktbm5QMVBZZXc?oc=5","date":"2024-01-18","type":"pipeline","source":"Neurology® Journals","summary":"Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure - Neurology® Journals","headline":"Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure - Neurology® Journals","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2022-09-25","type":"regulatory","source":"Medical Dialogues","summary":"AstraZeneca Ultomiris approved in Europe for treatment of adults with generalised myasthenia gravis - Medical Dialogues","headline":"AstraZeneca Ultomiris approved in Europe for treatment of adults with generalised myasthenia gravis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE41anFYbFFKeXBHY2VISUw3QW1FeU5wT09uNlctWEQ4NDd4RzIydWZZbXFIdnlzdmRrZTd4VkhNVGpBa3RsTWIyZTZILWFmQ2RRMXM4dERvZm9udWhyaDZUNFZvYW5mV0U0Zmc?oc=5","date":"2020-02-20","type":"pipeline","source":"Neurology® Journals","summary":"MYORG -related disease is associated with central pontine calcifications and atypical parkinsonism - Neurology® Journals","headline":"MYORG -related disease is associated with central pontine calcifications and atypical parkinsonism - Neurology® Journals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQX19NNW1kV19rXzlsVGF3aEFJME0xdDJYV0U0bVJVRjZWVlAzTnpOcVliQ1YtM2xndE8wQTIySC1tbW4xb1U2SUJnT2FhR1lqN2M4RzBXV0VYOEl1WEVNZ0RrMVlNOS1aNzZ5eVhHUDQ5R3RVaHRzYlBOaVl6T0N4WDczUWlscDlWY05rbHBmMTVnSHhiQmlQMGctdGZMY1hP?oc=5","date":"2019-01-12","type":"trial","source":"NeurologyLive","summary":"Amifampridine Phosphate Shows Success in Myasthenia Gravis Trial - NeurologyLive","headline":"Amifampridine Phosphate Shows Success in Myasthenia Gravis Trial","sentiment":"positive"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}